Redeye provides a research update following the Q3 report published by OncoZenge earlier today. The company reported a lower OPEX and cash burn than anticipated, managing to maintain a continued impressive cost control. All eyes are now on the decision regarding a definite partner agreement with Pharmanovia, set to be announced by the end of this month. For now, we reiterate our fair value range (SEK3 – SEK28) with a base case valuation of SEK14.